** Shares of drugmaker Merck MRK.N rise 1.5% to $101.57 premarket
** MRK and Chinese biotech Hansoh Pharma 3692.HK have signed global licensing deal for experimental obesity drug, HS-10535, co says
** Hansoh to receive $112 mln upfront and $1.9 bln in milestone payments
** MRK will take $112 mln charge before taxes in Q4 2024 as part of the deal
** 21 of 28 brokerages rate the stock "buy" or higher and 7 "hold"; their median PT is $130 - LSEG
** As of last close, stock has fallen 8.2% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。